A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus.

Clin Cancer ResOct 1, 2026
Clinical ResearchOncology (Medical)

Lucjan Wyrwicz, Arunee Dechaphunkul, Jong-Seok Lee et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase II randomized controlled trial evaluated the efficacy of bispecific antibodies lomvastomig and tobemstomig against nivolumab in 190 checkpoint inhibitor-naïve patients with advanced esophageal squamous cell carcinoma. The median overall survival was 4.8 months for lomvastomig, 6.7 months for tobemstomig, and 8.1 months for nivolumab, indicating that neither bispecific antibody improved survival compared to nivolumab.

Key findings

  • Median overall survival was 4.8 months for lomvastomig, 6.7 months for tobemstomig, and 8.1 months for nivolumab.
  • Objective response rates were 3.7% for lomvastomig, 9.8% for tobemstomig, and 8.6% for nivolumab.
  • Tobemstomig showed improved survival in PD-L1-high patients compared to PD-L1-low patients.
  • Adverse events for all treatments were manageable and consistent with known immune-mediated side effects.

Why it matters

The findings highlight the limited efficacy of lomvastomig and tobemstomig compared to nivolumab in advanced esophageal squamous cell carcinoma, emphasizing the importance of biomarker-guided treatment selection.

Source

PubMed · PMID 42440370

Published in Clin Cancer Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.